Eli Lilly raised its full-year profit and revenue forecasts on Thursday as strong appetite for its widely popular weight-loss and diabetes drugs Zepbound and Mounjaro helped it blow past third-quarter earnings estimates.
Eli Lilly Raises Forecasts On Surging Demand For Weight-Loss Drugs
About the Author: ryounglao
Leave A Comment